Esflurbiprofen transdermal - Taisho Pharmaceutical

Drug Profile

Esflurbiprofen transdermal - Taisho Pharmaceutical

Alternative Names: LOQOA Tape; S-Flurbiprofen; S-flurbiprofen transdermal; SFPP; TT-063

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tokuhon Corporation
  • Developer Taisho Pharmaceutical; Tokuhon Corporation
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Inflammation; Pain
  • No development reported Muscle pain; Periarthritis

Most Recent Events

  • 15 Feb 2018 Taisho Pharmaceutical plans a phase III trial for Osteoarthritis in February 2018 , (NCT03434197)
  • 05 Feb 2018 Phase-III clinical trials in Pain in Indonesia (Topical) (NCT03434197)
  • 26 Sep 2016 Taisho Pharmaceutical completes a phase II trial for Pain (in patients with knee osteoarthritis) in Japan (Transdermal) before September 2016 (JapicCTI090907)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top